IMM 20.3% 35.5¢ immutep limited

interest in new york, page-9

  1. 15,518 Posts.
    lightbulb Created with Sketch. 43
    The biggest issue Dendreon currently faces (after all the other problems they have had) is the emerging competition for Provenge from new drugs like Zytiga, from J&J.

    There's nothing currently within cooee of Cvac for Ovarian Cancer.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.